FDA
-
-
-
-
-
-
-
FDA approves Arcutis' roflumilast cream for plaque psoriasis in children 2+
-
-
-
-
-
-
-
The Credibility Filter Wall Street Uses to Sort Biotech Winners
-
-
-
-
-
-
-
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pedi
-
-
-
-
-
-
-
Arcutis projects ZORYVE sales of $455-470 million for 2026
-
-
-
-
-
-
-
Arcutis publishes long-term ZORYVE safety data for seborrheic dermatitis
-
-
-
-
-
-
-
Arcutis presents new ZORYVE data on sleep quality and long-term control
-
-
-
-
-
-
-
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
-
325,893 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

